DK1325033T3 - Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning - Google Patents

Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning

Info

Publication number: DK1325033T3
Authority: DK; Denmark
Prior art keywords: inhibition; treatment; delayed; acute vascular; activation
Prior art date: 2000-10-10

Application number

DK01977478.5T

Other languages

English (en)

Inventor

Michael S C Fung

Bill N C Sun

Cecily Sun

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-10

Filing date

2001-10-04

Publication date

2010-04-06

2001-10-04 Application filed by Genentech Inc filed Critical Genentech Inc

2010-04-06 Application granted granted Critical

2010-04-06 Publication of DK1325033T3 publication Critical patent/DK1325033T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Transplantation (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK01977478.5T 2000-10-10 2001-10-04 Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning DK1325033T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23930900P	2000-10-10	2000-10-10
PCT/US2001/031103 WO2002030985A2 (en)	2000-10-10	2001-10-04	Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection

Publications (1)

Publication Number	Publication Date
DK1325033T3 true DK1325033T3 (da)	2010-04-06

Family

ID=22901599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01977478.5T DK1325033T3 (da)	2000-10-10	2001-10-04	Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning

Country Status (11)

Country	Link
US (1)	US6534058B2 (da)
EP (5)	EP2281840A3 (da)
AT (1)	ATE449791T1 (da)
AU (1)	AU2001296594A1 (da)
CA (1)	CA2424379C (da)
DE (1)	DE60140618D1 (da)
DK (1)	DK1325033T3 (da)
ES (2)	ES2333775T3 (da)
HK (2)	HK1211043A1 (da)
PT (1)	PT1325033E (da)
WO (1)	WO2002030985A2 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20021527A1 (it)	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
NZ540735A (en) *	2002-12-02	2008-08-29	Resistentia Pharmaceuticals Ab	Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-C5 amino acid segment and a non-self amino acid segment
US20070123466A1 (en) *	2003-05-13	2007-05-31	New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery	Method of treating recurrent miscarriages
ATE498010T1 (de) *	2004-03-01	2011-02-15	Immune Disease Inst Inc	Natürliche igm-antikörper und inhibitoren davon
EP3056218A1 (en)	2004-05-14	2016-08-17	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2551202T5 (es) *	2005-11-04	2018-11-30	Genentech, Inc.	Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
AU2013200223B2 (en) *	2005-11-04	2015-08-20	Genentech, Inc.	Use of Complement Pathway Inhibitors to Treat Ocular Diseases
EP1988882B1 (en)	2006-03-02	2014-12-17	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
DK2359834T5 (da)	2006-03-15	2017-02-06	Alexion Pharma Inc	Behandling af paroxysmal natlig hæmoglobinuripatienter med en hæmmer af komplement
DK2006381T3 (da)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til regulering af antistoffers blodfarmakokinetik
EP2380907B1 (en) *	2006-09-05	2016-11-30	Alexion Pharmaceuticals, Inc.	Methods and compositions for the treatment of antibody mediated neuropathies
CN106084054A (zh) *	2006-11-02	2016-11-09	健泰科生物技术公司	人源化的抗‑d因子抗体
EP2148691B1 (en)	2007-02-05	2015-05-20	Apellis Pharmaceuticals, Inc.	Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
DK2202245T3 (da)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	Fremgangsmåde til modificering af et antistofs isoelektriske punkt via aminosyresubstitution i cdr
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
PT2708559T (pt)	2008-04-11	2018-05-16	Chugai Pharmaceutical Co Ltd	Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
WO2010015608A1 (en)	2008-08-05	2010-02-11	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
AU2014201433B2 (en) *	2008-08-05	2016-05-26	Novartis Ag	Compositions and methods for antibodies targeting complement protein C5
HRP20230487T1 (hr)	2009-02-13	2023-07-21	Immunomedics, Inc.	Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti
CN102482701B (zh)	2009-09-16	2015-05-13	免疫医疗公司	I类抗-cea抗体及其使用
CA2782194C (en)	2009-12-02	2018-01-16	Immunomedics, Inc.	Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
MX365235B (es)	2010-11-30	2019-05-28	Chugai Pharmaceutical Co Ltd	Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
JP6024025B2 (ja)	2011-05-02	2016-11-09	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	少容量投与用のアロタイプ選択抗体の限外濾過濃縮
CN103796667A (zh)	2011-06-22	2014-05-14	艾普莱斯制药公司	用补体抑制剂治疗慢性障碍的方法
CA2859493A1 (en)	2011-12-21	2013-06-27	Novartis Ag	Compositions and methods for antibodies targeting factor p
WO2013126006A1 (en)	2012-02-20	2013-08-29	Swedish Orphan Biovitrum Ab (Publ)	Polypeptides binding to human complement c5
AU2013302696B9 (en)	2012-08-14	2018-08-09	Ibc Pharmaceuticals, Inc.	T-cell redirecting bispecific antibodies for treatment of disease
TW201418707A (zh) *	2012-09-21	2014-05-16	Alexion Pharma Inc	補體組分ｃ５拮抗劑之篩選分析
CA2891673C (en)	2012-11-15	2025-10-07	Apellis Pharmaceuticals Inc	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
PL2900277T3 (pl)	2012-12-13	2022-05-16	Immunomedics, Inc.	Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
AU2014213147B2 (en) *	2013-01-31	2019-01-17	lmmunAbs Inc.	C5 antibody and method for preventing and treating complement-related diseases
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
CR20160132A (es)	2013-08-12	2016-08-25	Genentech Inc	Composiciones y método para tratar condiciones asociadas con el complemento
KR102497083B1 (ko)	2013-08-28	2023-02-07	애피바디 에이비	돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
PT3038633T (pt)	2013-08-28	2021-01-14	Ipc Res Llc	Polipéptidos estáveis que se ligam ao complemento humano c5
JP6447933B2 (ja)	2014-02-21	2019-01-09	アイビーシーファーマスーティカルズ，インコーポレイテッド	Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
US9139649B2 (en)	2014-02-25	2015-09-22	Immunomedics, Inc.	Humanized anti-CD22 antibody
SG11201608868PA (en)	2014-05-01	2016-11-29	Genentech Inc	Anti-factor d antibody variants and uses thereof
WO2015200260A1 (en)	2014-06-24	2015-12-30	Immunomedics, Inc.	Anti-histone therapy for vascular necrosis in severe glomerulonephritis
AU2015328370B2 (en)	2014-10-07	2021-08-05	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
HUE056489T2 (hu)	2014-12-19	2022-02-28	Chugai Pharmaceutical Co Ltd	Anti-C5 antitestek és alkalmazási eljárások
MX2017005774A (es)	2014-12-19	2017-07-28	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
CA2981543A1 (en)	2015-04-22	2016-10-27	Immunomedics, Inc.	Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
PT3313443T (pt)	2015-06-25	2023-08-30	Immunomedics Inc	Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl)	2015-07-01	2021-12-06	Immunomedics, Inc.	Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
JP6968787B2 (ja)	2015-10-07	2021-11-17	アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc.	投与レジメン
TW201718014A (zh)	2015-10-12	2017-06-01	諾華公司	C5抑制劑於移植相關微血管病之用途
EP3368090A1 (en)	2015-10-30	2018-09-05	H. Hoffnabb-La Roche Ag	Anti-factor d antibody variant conjugates and uses thereof
EP3368074A2 (en)	2015-10-30	2018-09-05	Hoffmann-La Roche AG	Anti-factor d antibodies and conjugates
MY191668A (en)	2016-06-14	2022-07-06	Regeneron Pharma	Anti-c5 antibodies and uses thereof
KR102538749B1 (ko)	2016-08-05	2023-06-01	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
CN110167961A (zh)	2017-01-31	2019-08-23	中外制药株式会社	用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
US11040107B2 (en)	2017-04-07	2021-06-22	Apellis Pharmaceuticals, Inc.	Dosing regimens and related compositions and methods
JP2021506241A (ja)	2017-12-13	2021-02-22	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗ｃ５抗体組み合わせ物およびその使用
KR20240167712A (ko)	2017-12-15	2024-11-27	아펠리스 파마슈티컬스 인코포레이티드	투여 요법 및 관련 조성물 및 방법
MY210523A (en)	2018-08-01	2025-09-29	Univ Osaka	A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN114929273A (zh)	2019-07-31	2022-08-19	豪夫迈·罗氏有限公司	通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
AU2020319677A1 (en)	2019-07-31	2022-01-06	F. Hoffmann-La Roche Ag	Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
WO2021067526A1 (en)	2019-10-02	2021-04-08	Alexion Pharmaceuticals, Inc.	Complement inhibitors for treating drug-induced complement-mediated response
CN111171149B (zh) *	2020-02-23	2021-09-07	北京康普美特创新医药科技有限责任公司	一种抗补体c5分子的人源化单链抗体及其应用
WO2021231720A1 (en)	2020-05-15	2021-11-18	Alexion Pharmaceuticals, Inc.	Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN114149501B (zh) *	2020-12-11	2023-05-26	天士力生物医药股份有限公司	抗c5抗体及其应用
US20250073349A1 (en)	2021-05-10	2025-03-06	Kawasaki Institute Of Industrial Promotion	Antibody having reduced binding affinity for antigen
WO2024238422A1 (en)	2023-05-12	2024-11-21	Alexion Pharmaceuticals, Inc.	Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en)	2023-05-12	2024-11-21	Alexion Pharmaceuticals, Inc.	Use of biomarkers for the identification and treatment of complement-mediated disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5896026A (ja)	1981-10-30	1983-06-07	Nippon Chemiphar Co Ltd	新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en)	1982-06-24	1986-09-02	Japan Chemical Research Co., Ltd.	Long-acting composition
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5506247A (en)	1988-04-15	1996-04-09	T Cell Sciences, Inc.	Compounds that inhibit complement and/or suppress immune activity
US6395888B1 (en) *	1996-02-01	2002-05-28	Gilead Sciences, Inc.	High affinity nucleic acid ligands of complement system proteins
US5679546A (en)	1993-09-24	1997-10-21	Cytomed, Inc.	Chimeric proteins which block complement activation
DE69533921T2 (de) *	1994-03-23	2005-12-01	Alexion Pharmaceuticals, Inc., New Haven	Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US6074642A (en) *	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en)	1994-06-02	1997-10-21	The Johns Hopkins University	Method for preventing complement-dependent rejection of organ or tissue transplants
US5546808A (en)	1994-09-06	1996-08-20	Harris Instrument Corporation	Apparatus and method for binocular measurement system
US5463564A (en)	1994-09-16	1995-10-31	3-Dimensional Pharmaceuticals, Inc.	System and method of automatically generating chemical compounds with desired properties
JP2000505068A (ja)	1996-03-13	2000-04-25	トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア	補体活性化を阻害する新規ペプチド類
WO1998046248A1 (en)	1997-04-14	1998-10-22	Anderson Byron E	Method and material for inhibiting complement
ES2258817T3 (es)	1997-05-21	2006-09-01	Biovation Limited	Metodo para la produccion de proteinas no inmunogenas.
US6333034B1 (en)	1997-08-26	2001-12-25	Gliatech, Inc.	Process for inhibiting complement activation via the alternative pathway

2001
- 2001-10-04 AU AU2001296594A patent/AU2001296594A1/en not_active Abandoned
- 2001-10-04 EP EP10179315A patent/EP2281840A3/en not_active Withdrawn
- 2001-10-04 WO PCT/US2001/031103 patent/WO2002030985A2/en not_active Ceased
- 2001-10-04 EP EP01977478A patent/EP1325033B1/en not_active Expired - Lifetime
- 2001-10-04 AT AT01977478T patent/ATE449791T1/de active
- 2001-10-04 ES ES01977478T patent/ES2333775T3/es not_active Expired - Lifetime
- 2001-10-04 PT PT01977478T patent/PT1325033E/pt unknown
- 2001-10-04 EP EP16152143.0A patent/EP3031827A1/en not_active Withdrawn
- 2001-10-04 DK DK01977478.5T patent/DK1325033T3/da active
- 2001-10-04 CA CA2424379A patent/CA2424379C/en not_active Expired - Lifetime
- 2001-10-04 DE DE60140618T patent/DE60140618D1/de not_active Expired - Lifetime
- 2001-10-04 EP EP15154800.5A patent/EP2896631A1/en not_active Withdrawn
- 2001-10-04 US US09/682,672 patent/US6534058B2/en not_active Expired - Lifetime
- 2001-10-04 ES ES09167955.5T patent/ES2483991T3/es not_active Expired - Lifetime
- 2001-10-04 EP EP09167955.5A patent/EP2113516B1/en not_active Expired - Lifetime
2015
- 2015-12-02 HK HK15111863.4A patent/HK1211043A1/en unknown
2016
- 2016-12-07 HK HK16113934.4A patent/HK1225741A1/en unknown

Also Published As

Publication number	Publication date
EP2896631A1 (en)	2015-07-22
ES2483991T3 (es)	2014-08-08
US20020041875A1 (en)	2002-04-11
PT1325033E (pt)	2010-04-15
WO2002030985A2 (en)	2002-04-18
EP2113516A1 (en)	2009-11-04
WO2002030985A3 (en)	2002-12-05
HK1225741A1 (en)	2017-09-15
HK1211043A1 (en)	2016-05-13
ES2333775T3 (es)	2010-03-01
CA2424379A1 (en)	2002-04-18
EP3031827A1 (en)	2016-06-15
ATE449791T1 (de)	2009-12-15
DE60140618D1 (de)	2010-01-07
EP1325033B1 (en)	2009-11-25
US6534058B2 (en)	2003-03-18
EP1325033A2 (en)	2003-07-09
CA2424379C (en)	2013-10-01
EP2113516B1 (en)	2014-05-21
HK1134508A1 (en)	2010-04-30
AU2001296594A1 (en)	2002-04-22
EP2281840A2 (en)	2011-02-09
EP2281840A3 (en)	2012-05-23

Publication	Publication Date	Title
DK1325033T3 (da)	2010-04-06	Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
NO2006008I2 (no)	2009-06-15	Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
DK1054693T3 (da)	2008-12-08	Inhibitorer af komplementaktivering
DK1265929T3 (da)	2009-11-16	Anti-C2/C2a-inhibitorer til komplement aktivering
KR960704576A (ko)	1996-10-09	CD40에 대한 항체(Antibodies to CD40)
WO2007062245A3 (en)	2007-12-06	Human monoclonal antibody human cd134 (ox40) and methods of making and using same
BRPI9809387B8 (pt)	2021-05-25	anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
WO1998057994A3 (en)	1999-03-25	Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
NZ611387A (en)	2015-05-29	Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
ATE421976T1 (de)	2009-02-15	Fab fragmentbibliotheken und verfahren für deren verwendung
TW200722518A (en)	2007-06-16	Sc(fv)2 structural isomers
ATE509955T1 (de)	2011-06-15	Humanisierte kollagen-antikörper und damit verbundene verfahren
PE20061323A1 (es)	2007-02-09	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
EP1411962A4 (en)	2005-02-02	TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
DE69942668D1 (de)	2010-09-23	Humanisierter monoklonaler antikörper gegen von-willebrand faktor
WO2003075846A3 (en)	2005-08-11	Uses of monoclonal antibody 8h9
ATE486892T1 (de)	2010-11-15	Verfahren zur kontrolle von krebs
DE69922834D1 (de)	2005-01-27	Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
EA200870072A1 (ru)	2009-04-28	ПРОТИВОВОСПАЛИТЕЛЬНЫЕ dAb
WO2001051644A3 (de)	2001-12-06	ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN
GB0031448D0 (en)	2001-02-07	Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
ATE370163T1 (de)	2007-09-15	Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
DK1222929T3 (da)	2010-09-06	Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
DK1334983T3 (da)	2006-06-26	Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII
IL139571A0 (en)	2002-02-10	A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same